INDIGENOUS MICROALGA (CHLORELLA SOROKINIANA SM1) ISOLATION, CARBON CAPTURE POTENTIAL AND PHARMACEUTICAL METABOLITE PROFILING
在来微細藻類（クロレラ・ソロキニアナSM1）の分離、二酸化炭素捕捉能及び創薬代謝物プロファイリング (AI 翻訳)
Minaj Mulani, Vidya Kothari, S J Manoj Pawar, Harichandra Nikule, Sunil Bhagat, Parimita Jadhav, Jayant Pralhad Rathod
🤖 gxceed AI 要約
日本語
この研究は、インドの現地から単離された微細藻類Chlorella sorokiniana SM1株の二酸化炭素捕捉能と医薬品代謝物の可能性を調査した。理論的なCO2捕捉量は既知の株より37.5%高い1.33g/g biomassを示し、23種類の生理活性物質が確認された。気候変動緩和と医薬品開発の両面で有望な株である。
English
This study isolated an indigenous microalgal strain Chlorella sorokiniana SM1 from Indian soil and assessed its carbon capture potential and pharmaceutical metabolite profile. The strain exhibited theoretical carbon capture of 1.33 g CO2/g biomass, 37.5% higher than a known comparator, and produced 23 bioactive compounds with potential antibacterial, antiviral, and anticancer properties. The findings support dual-use of microalgae for climate mitigation and pharmaceutical sustainability.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本のGX文脈では、CCUS技術の一つとして微細藻類による炭素固定が注目されている。本論文はインドの在来株を用いているが、日本の気候や廃水処理との親和性を検討するための基礎データを提供する可能性がある。ただし、実用化には大規模培養やコスト評価が必要であり、直接的な政策連携は弱い。
In the global GX context
In the global GX context, microalgae-based carbon capture is explored as a biological CCUS pathway. This paper contributes strain-level performance data (theoretical CO2 uptake per biomass) that could inform bioprospecting for carbon capture applications. However, it lacks techno-economic analysis or integration with industrial point sources, limiting immediate transition finance relevance.
👥 読者別の含意
🔬研究者:Provides reference data on a novel microalgae strain with enhanced carbon capture and bioactive compound production for further bioprospecting and metabolic engineering.
🏢実務担当者:Could be relevant for companies exploring biological carbon capture or algae-based co-product opportunities, but at early stage.
📄 Abstract（原文）
Background: Microalgae are becoming widely recognized as efficient agents for sustainable carbon capture and bioactive metabolite production with potent pharmaceutical applications. At present there is an argent need for biobased pharmaceutical bio compounds. Objectives: To isolate new microalgal species for carbon capture and utilization as biopharma products and confirm the presence of bioactive compounds. Methods: Traditional methods of serial dilutions from soil, monoculture establishment, morphological analysis, axenic culture development, molecular identification were carried out for the identification of indigenous microalgal species. Microalga Chlorella sorokiniana SM1 growth analysis, pigment profile and theoretical carbon capture potential was carried out. The LCMS analysis was performed using Chlorella sorokiniana SM1 extract for the identification of potential pharmaceutical compounds. Results: The indigenous microalga Chlorella sorokiniana SM1, a novel strain, was isolated, made axenic and identified using molecular techniques. The cells were spherical in size and were around 2.68 µm in diameter. The biomass of isolated Chlorella sorokiniana SM1 strain was 0.74 g/L as compared to 0.63 g/L of already known Chlorella sorokiniana species used for comparison purposes. The theoretical C capture potential of the isolated Chlorella sorokiniana SM1 and Chlorella sorokiniana were calculated to be 1.33 and 1.13g/g biomass respectively, which was 37.5% higher. Chlorophyll a, b and carotenoids of the isolated strain were found to be 14%, 16& and 33% greater than that of known Chlorella sorokiniana. Also, 23 unique bioactive substances, including metabolites with possible antibacterial, antiviral, anticancer, antidiabetic, antioxidant, and anti-inflammatory qualities, were found by LC-MS analysis. Conclusion: Overall, the findings highlight the dual utility of Chlorella sorokiniana SM1 in climate change mitigation and pharmaceutical applications, positioning C. sorokiniana SM1 as a promising candidate for integrated environmental and pharmaceutical industry sustainability.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.25258/ijddt.16.48s.79first seen 2026-06-11 05:30:47
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。